World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
78
Citations
38472
World Ranking
1715
National Ranking
151

Overview

Teresa Lambe is affiliated with the University of Oxford in the United Kingdom and has contributed extensively to research in the field of Medicine, with a focus on Infectious Diseases, Immunology, Molecular Biology, Epidemiology, and Health. Their scholarly work centers predominantly on SARS-CoV-2 and COVID-19 research, COVID-19 clinical research studies, vaccine coverage and hesitancy, animal virus infections studies, immunotherapy and immune responses, vaccines and immunoinformatics approaches, and COVID-19 epidemiological studies.

Their frequent publication venues include:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • SSRN Electronic Journal
  • Nature Communications
  • The Lancet
  • Journal of Infection

Some of the notable recent papers by Teresa Lambe include:

  • Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK (2020, The Lancet)
  • Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (2020, The Lancet)
  • Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant (2021, New England Journal of Medicine)
  • Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection (2021, Nature Medicine)
  • Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials (2021, The Lancet)

Within their collaborative network, Teresa Lambe frequently works with these co-authors:

  • Sarah C. Gilbert
  • Andrew J. Pollard
  • Sagida Bibi
  • Parvinder K. Aley
  • Sandra Belij-Rammerstorfer

Best Publications

  • Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

    M Voysey;Clemens Sac.;S A Madhi;L Y Weckx

  • Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

    P M Folegatti;K J Ewer;P K Aley;B Angus

  • SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

    Unknown

  • Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

    M Voysey;S A Costa Clemens;S A Madhi;L Y Weckx

  • Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

    Unknown

  • Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.

    S. A. Madhi;V. Baillie;C. L. Cutland;M. Voysey

  • Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

    M N Ramasamy;A M Minassian;K J Ewer;A L Flaxman

  • Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.

    Shuo Feng;Daniel J. Phillips;Thomas White;Homesh Sayal

  • ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.

    Neeltje van Doremalen;Teresa Lambe;Alexandra Spencer;Sandra Belij-Rammerstorfer

  • Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.

    D Zhou;W Dejnirattisai;P Supasa;C Liu

  • A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity

    Carola G. Vinuesa;Matthew C. Cook;Constanza Angelucci;Vicki Athanasopoulos

  • Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

    Pedro M Folegatti;Katie J Ewer;Parvinder K Aley;Brian Angus

  • Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

    Unknown

  • Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.

    C Liu;H M Ginn;W Dejnirattisai;P Supasa

  • Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

    Katherine R W Emary;Tanya Golubchik;Parvinder K Aley;Cristina V Ariani

  • DNA repair is limiting for haematopoietic stem cells during ageing

    Anastasia Nijnik;Lisa Woodbine;Caterina Marchetti;Caterina Marchetti;Sara Dawson

  • T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

    K J Ewer;Barrett;S Belij-Rammerstorfer;H Sharpe

  • Antibody evasion by the P.1 strain of SARS-CoV-2.

    W Dejnirattisai;D Zhou;P Supasa;C Liu

  • Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.

    Xinxue Liu;Robert H Shaw;Arabella S V Stuart;Melanie Greenland

  • Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.

    P Supasa;D Zhou;W Dejnirattisai;C Liu

  • Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

    Alasdair P S Munro;Alasdair P S Munro;Leila Janani;Victoria Cornelius;Parvinder K Aley

  • Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1

    Tamara K. Berthoud;Matthew Hamill;Patrick J. Lillie;Lenias Hwenda

  • Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine (preprint)

    Voysey, Merryn, Costa Clemens, Sue Ann, Madhi, Shabir A.;Weckx, Lily Yin, Folegatti, Pedro M.;Parvinder K. Aley;Angus, Brian John, Baillie, Vicky, Barnabas, Shaun L.

Frequent Co-Authors

Sarah C. Gilbert
Sarah C. Gilbert University of Oxford
Andrew J. Pollard
Andrew J. Pollard University of Oxford
Katie J. Ewer
Katie J. Ewer University of Oxford
Miles W. Carroll
Miles W. Carroll University of Oxford
Daniel B. Wright
Daniel B. Wright University of Nevada, Las Vegas
Richard J. Cornall
Richard J. Cornall University of Oxford
Paul Klenerman
Paul Klenerman University of Oxford
Gavin R. Screaton
Gavin R. Screaton University of Oxford
Adrian V. S. Hill
Adrian V. S. Hill University of Oxford
Susanna Dunachie
Susanna Dunachie University of Oxford

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related healthcare degrees can open up diverse career opportunities. Many students consider accelerated nursing programs to enter the medical field quickly. Programs like accelerated FNP programs allow individuals with a non-nursing background to fast-track their journey toward becoming Family Nurse Practitioners.

Similarly, online options such as online ABSN programs for non nurses provide accessible pathways for career changers. These programs are tailored to accommodate busy schedules while delivering essential nursing knowledge efficiently.

Once you begin your nursing career, acquiring specialized credentials like acute care nurse practitioner certification can help you focus on high-acuity patient care, which is vital in immunology-focused healthcare settings.

For those just starting out, exploring the easiest ABSN program to get into can provide a smoother entry into nursing education. This can be a strategic first step before advancing into more specialized immunology or nurse practitioner roles.

Best Scientists Citing Teresa Lambe

Trending Scientists